CSC Awarded Follow-on Healthcare Contract Worth up to $90 Million over 10 Years
News Release -- January 20, 2015
CSC’s DynPort Vaccine Company will Continue Supporting Clinical Trials to Evaluate Anti-Infective Drugs for the National Institute of Allergy and Infectious Diseases
FALLS CHURCH, Va.--(BUSINESS WIRE)-- CSC (NYSE: CSC) announced today that its company, DynPort Vaccine Company LLC (DVC), received a follow-on contract to continue supporting the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. Valued at up to $90 million, the award is a 10-year Indefinite Delivery/Indefinite Quantity contract to support and conduct Phase 1 clinical trials of infectious disease therapeutics.
Under the agreement, DVC and its teaming partners, Quintiles, Health Decisions and WCCT Global, will support and manage Phase 1 clinical trial units to assess the safety of investigational therapeutic products being studied by NIAID, and determine pharmacokinetic and pharmacodynamic properties, which will inform appropriate human dosing regimens. As the prime contractor, DVC will manage the overall program and clinical operations, quality assurance and co-development of protocols and concepts. Quintiles, Health Decisions and WCCT Global will provide clinical research and support services for the implementation and conduct of approved clinical trial protocols. Trials will include therapeutic candidates for a broad range of infectious diseases, and investigational products tested will include those to protect against viral (other than HIV), bacterial, parasitic and fungal pathogens, including NIAID priority biodefense pathogens and emerging and re-emerging infectious diseases.
“DVC is pleased to continue supporting clinical trials to evaluate anti-infective drugs for NIAID,” said Dr. Gary S. Nabors, president of DVC. “We have enjoyed a history of success under our existing NIAID contract and together with our teaming partners, look forward to continuing our work with NIAID to evaluate new compounds for their potential to meet the growing need for new anti-infectives.”
Under the existing contract with NIAID awarded in 2008, DVC has completed four Phase 1 trials, while continuing to progress on three others. DVC also developed study protocols and clinical trial concepts for NIAID under separate task orders. Adding Health Decisions and WCCT Global, both small businesses, to the new contract increases DVC’s access to Phase 1 units across the United States and provides greater flexibility and efficiencies to NIAID.
About DynPort Vaccine Company LLC (DVC)
DVC manages product development programs and provides consulting, technical and program management services to U.S. government agencies and companies in the biotechnology and pharmaceutical industries. DVC is part of CSC's North American Public Sector. CSC’s expertise in providing health services to government agencies has grown over the last five decades to offer commercial best practices integrated to meet federal, state and local healthcare requirements. Services range from optimizing claims processing to operating disease surveillance systems to vaccine development and management. CSC's thought leadership and solutions are improving the quality of healthcare with better information for better decisions to save lives and money.
Computer Sciences Corporation (CSC) is a global leader of next-generation information technology (IT) services and solutions. The Company's mission is to enable superior returns on our clients’ technology investments through best-in-class industry solutions, domain expertise and global scale. CSC has approximately 76,000 employees and reported revenue of $12.9 billion for the 12 months ended Oct. 3, 2014.
This project has been funded in whole or in part with Federal (United States Government) funds from the National Institute of Allergy and Infectious Diseases (NIAID), Division of Microbiology and Infectious Diseases (DMID), under contract Number HHSN272201500005I. Pursuant to section 507 of P.L. 104-208 and Section 508 of P.L. 105-78, 100% of the total of this project’s costs are financed with Federal funds. The content of this publication does not necessarily reflect the views or policies of the United States Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.